Healthcare Industry News: Auriga Laboratories
News Release - July 5, 2007
Auriga Laboratories Appoints Rick Coulon Vice President of Consumer Brands
LOS ANGELES--(HSMN NewsFeed)--Auriga Laboratories, Inc. (OTCBB:ARGA ), a specialty pharmaceutical company with products for the treatment of Xerostomia, dermatological conditions, and acute respiratory diseases, announced today that it has appointed Rick Coulon to the position of Vice President of Consumer Brands. Mr. Coulon has more than 20 years of experience marketing healthcare and consumer brands. He joins Auriga from StoneBridge Pharma a division of Stiefel Laboratories, the world's largest independent pharmaceutical company specializing in dermatology, where he was Executive Director of Marketing."I am pleased that we were able to expand our management team through the addition of Rick," said Philip S. Pesin, CEO of Auriga. "He has extensive experience in launching and building successful pharmaceutical and consumer brands, and his recent success at a leading specialty pharmaceutical company should serve us well as we continue our growth."
Prior to joining StoneBridge, he was Director of Marketing and Hospital Sales for Mallinckrodt Pharmaceuticals, where he was responsible for managing and driving growth of its narcotic pharmaceutical business with annual sales of over $300 million. He contributed to a 25% growth in sales by developing and executing new marketing and product strategies. Before joining Mallinckrodt he was Executive Director of Sales & Marketing for Akorn, Inc., where he managed Ophthalmic pharmaceutical/device & Injectible pharmaceutical business units with annual sales of $60 million.
He was a Senior Marketing Manager at ConAgra Foods, where he managed a portfolio of products, which reached annual sales of over $250 million consumption and household penetration to peak levels. He achieved record revenues through product repositioning, packaging, new product introductions, and consumer promotion. Prior to joining ConAgra, he spent 10 years at Ciba Vision Corporation a subsidiary of Novartis, where he managed a portfolio of OTC eye care products in North America achieving unsurpassed sales and profitability with total sales of over $135 million.
Mr. Coulon received a Bachelor of Arts Degree from Michigan State University.
About Auriga Laboratories(TM)
Auriga Laboratories is a specialty pharmaceutical company building an industry changing commission based-sales model. The company's high-growth business model combines driving revenues through a variable cost commission-based sales structure, acquisition of proven brand names, introduction of new brands, and a strategic development pipeline, all of which is designed to enhance its growing direct relationships with physicians nationwide. Auriga's exclusive prescription and over-the-counter product portfolio includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), ExtendrylŽ, and LevallŽ families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.
Forward-Looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the estimated market for nasal sprays, the development of additional products, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.
Source: Auriga Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
